Investor Relations

News Release

Printer Friendly Version View printer-friendly version
<< Back
KemPharm to Present at Upcoming Investor Conferences

Management Presentations to Focus on Depth of Product Pipeline

CORALVILLE, Iowa, Feb. 07, 2017 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, announced today that President and Chief Executive Officer, Travis Mickle, Ph.D., will present at the following five investor conferences during February and March.

Details of KemPharm's presentations are as follows:

Event:   BIO CEO & Investor Conference
Date:    Tuesday, February 14, 2017
Time:    11:30 a.m. (ET)
Location:   The Waldorf Astoria, New York, NY

Event:   RBC Capital Markets 2017 Global Healthcare Conference
Date:    Wednesday, February 22, 2017
Time:    9:00 a.m. (ET)
Location:   The New York Palace Hotel, New York, NY

Event:   Cowen & Co. 36th Annual Health Care Conference 2017
Date:    Tuesday, March 7, 2017
Time:    8:00 a.m. (ET)
Location:   The Boston Marriott Copley Place, Boston, MA

Event:   29th Annual ROTH Conference
Date:    Conference Date March 12-15, 2017
Time:    Presentation date/time to be scheduled
Location:   The Ritz Carlton, Dana Point, CA

Event:   Oppenheimer & Co. 27th Annual Healthcare Conference
Date:    Tuesday, March 21, 2017
Time:    9:45 a.m. (ET)
Location:   The Westin New York Grand Central, New York, NY

All presentation webcasts will available on the Investor Relations section of the KemPharm website at following delivery at the respective conferences.

About KemPharm

KemPharm is a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs to treat serious medical conditions through its Ligand Activated Therapy (LAT) platform technology.  KemPharm utilizes its LAT platform technology to generate improved prodrug versions of FDA-approved drugs in the high need areas of pain, attention deficit hyperactivity disorder (ADHD) and other central nervous system disorders. KemPharm’s co-lead clinical development candidates are KP415, an extended-release prodrug of methylphenidate for the treatment of ADHD, and KP201/IR, an acetaminophen-free formulation of the company’s immediate release abuse deterrent hydrocodone product candidate, KP201.  For more information on KemPharm and its pipeline of prodrug product candidates visit

Investor Contacts:
Jason Rando / Joshua Drumm, Ph.D.
Tiberend Strategic Advisors, Inc.
212-375-2665 / 2664

Media Contact:
Daniel L. Cohen
Executive VP, Government and Public Relations
KemPharm, Inc.

Primary Logo